{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-malignant-skin-ulcer/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"28f3598f-1a0b-5fa6-885c-7908290eef3d","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field b28d5414-38e9-4ecd-b6ab-b48186dfe67a --><h2>Changes</h2><!-- end field b28d5414-38e9-4ecd-b6ab-b48186dfe67a -->","summary":null,"htmlStringContent":"<!-- begin item 72a5725e-5cec-4e59-b37b-8ee3dcc11a7c --><!-- begin field c996a245-f023-4296-bf33-bfb39781ec05 --><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>July 2015 to October 2016</strong> — reviewed. Literature searches were conducted in September 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been structural changes to the topic and changes to the recommendations have been updated in line with NICE guidance <em>Care of dying adults in the last days of life </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-malignant-skin-ulcer/references/\">NICE, 2015</a>].</p><!-- end field c996a245-f023-4296-bf33-bfb39781ec05 --><!-- end item 72a5725e-5cec-4e59-b37b-8ee3dcc11a7c -->","topic":{"id":"a66236f8-759a-578d-b8e0-d9b9f4d4b17b","topicId":"594ae15d-e8a6-49e1-9bc4-b8235684b211","topicName":"Palliative care - malignant skin ulcer","slug":"palliative-care-malignant-skin-ulcer","lastRevised":"Last revised in October 2018","chapters":[{"id":"8aae23f3-652c-5220-96a9-570f5c6a4197","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3fae4ef2-1de8-537a-8d87-bb0f0e925ca2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7cd1b72b-f0ca-5fa9-a739-760c7315a4c6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"28f3598f-1a0b-5fa6-885c-7908290eef3d","slug":"changes","fullItemName":"Changes"},{"id":"ee67bddb-c899-5cdf-8bd4-b6ce53a64863","slug":"update","fullItemName":"Update"}]},{"id":"7209a66f-e985-5a26-b178-2d841634478d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a512b109-ae33-58f1-9b3e-1bb25ba17ed1","slug":"goals","fullItemName":"Goals"},{"id":"d4f96da2-1dfd-5b18-aeec-d33fe0b56967","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ec220b93-2051-5b93-ada7-66029759c688","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e8a03776-8e6f-57f0-9d78-72e639758d72","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a89f6107-4d65-56f2-a108-583acc3aa1dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"99d9f654-11a9-5749-882a-6bfac0a995ad","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba712e36-e31f-53bb-9746-10f4bb36e7e9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ae192ef-3ead-55f6-b5dc-e15c6fbe8e92","slug":"definition","fullItemName":"Definition"},{"id":"6045e3e4-960f-5f2a-949e-66eaa7d7fd27","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"fb13b65f-08f4-5ac4-b21a-bbba9bec2bce","slug":"complications","fullItemName":"Complications"}]},{"id":"5750038d-2dca-5b1b-9cef-5ec97727cd6c","fullItemName":"Management","slug":"management","subChapters":[{"id":"576c0eda-301a-5d5f-9d9f-34505854cac8","slug":"palliative-cancer-care-malignant-skin-ulcer","fullItemName":"Scenario: Palliative cancer care - malignant skin ulcer"},{"id":"4c917ea3-8a66-5e50-9cd2-a4494533a824","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"c6fd3a21-3f33-5f10-9f9b-22da77001d52","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"cce56ef7-baec-5a1f-9927-a88b697e0b79","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"6fb5a8ca-5e8b-5cea-9647-c8d15aa9fd31","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c16178c4-497b-57f0-8903-94f79dc3e888","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0676abc6-76ab-5fcf-816a-0f0fd3c08737","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7c58ec18-ffff-5082-9660-ff776be47414","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"ec9b77b3-9f46-5d3d-89fe-1d2ba54e8e03","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b921fab-b857-5da1-90cd-616aa087e15a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f5f487fa-4ace-58e9-aefa-a01924f86557","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0a5cfba7-db2d-58b1-b705-aef0029b384e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7cd1b72b-f0ca-5fa9-a739-760c7315a4c6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"987e7251-54b1-5145-88f0-c92e93fd4133","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 1092a7a2-f8fd-4ec7-9355-eec6469d1808 --><h3>Previous changes</h3><!-- end field 1092a7a2-f8fd-4ec7-9355-eec6469d1808 -->","summary":null,"htmlStringContent":"<!-- begin item 4784c470-976e-4d88-88de-662fbe3c4a35 --><!-- begin field 982cb973-9fff-46ca-b59d-eb05124c2c2c --><p><strong>July 2015 </strong>—<strong> </strong>topic title changed to reflect broader topic coverage than specifically cancer care.</p><p><strong>May 2015 </strong>—<strong> </strong>reviewed and updated. A literature search was conducted in January 2015 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic structure has been altered to reflect a symptom-based approach and changes to antibiotic prescribing advice have been made.</p><p><strong>June 2013 </strong>— minor update. The 2013 QOF options for local implementation have been added to this topic.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 QOF indicators have been added to this topic. Issued in April 2012.</p><p><strong>May 2011 </strong>— minor update. The 2011/2012 QOF indicators have been added to this topic. Issued in June 2011.</p><p><strong>April to July 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008 </strong>— minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>October to December 2005 </strong>— reviewed. Validated in March 2006 and issued in May 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>September 2002 </strong>— written. Validated in October 2002 and issued in December 2002.</p><!-- end field 982cb973-9fff-46ca-b59d-eb05124c2c2c --><!-- end item 4784c470-976e-4d88-88de-662fbe3c4a35 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}